Is there a vaccine for Neisseria meningitidis type B?
The FDA is announcing the approval of Trumenba, the first vaccine approved in the United States to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. Trumenba is manufactured by Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
Are there vaccines for Neisseria meningitidis?
Vaccines can help prevent meningococcal disease, which is any type of illness caused by Neisseria meningitidis bacteria. There are 2 types of meningococcal vaccines available in the United States: Meningococcal conjugate or MenACWY vaccines (Menactra®, Menveo®, and MenQuadfi®)
What type of vaccines are serogroup B meningococcal vaccines?
Serogroup B meningococcal (MenB) vaccines can help prevent meningococcal disease caused by serogroup B. Other meningococcal vaccines are recommended to help protect against serogroups A, C, W, and Y.
When did meningitis B vaccine start?
On 14 June 2012, the FDA approved a combination vaccine against two types of meningococcal disease and Hib disease for infants and children 6 weeks to 18 months old. The vaccine, Menhibrix, prevents disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b.
What is the meningococcal B vaccine?
The meningococcal B vaccine (MenB) protects against a fifth type of meningococcal bacterium (called type B). It is fairly new and not yet recommended as a routine vaccination for healthy people. But some kids and teens who are at increased risk for meningococcal disease should get it starting from age 10.
Is meningococcal B vaccine safe?
However, as with any vaccine, side effects can occur. Available data suggest that MenB vaccines are safe. More than half of the people who get a MenB vaccine have mild problems following vaccination: Soreness, redness, or swelling where the shot was given.
Who is the meningococcal B vaccine recommended for?
Meningococcal B vaccines are recommended for people 10 years or older who are at increased risk for serogroup B meningococcal disease, including: People at risk because of a serogroup B meningococcal disease outbreak. Anyone whose spleen is damaged or has been removed, including people with sickle cell disease.
How effective is meningitis B vaccine?
The adjusted vaccine effectiveness against meningococcal group B disease was 52.7% (95% confidence interval [CI], −33.5 to 83.2) with a two-dose priming schedule for infants and 59.1% (95% CI, −31.1 to 87.2) with a two-dose priming schedule plus a booster at 1 year).
What’s in the meningitis B vaccine?
Serogroup B Meningococcal or MenB Vaccines 50 µg each of recombinant proteins Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and factor H binding protein (fHbp) 25 µg of Outer Membrane Vesicles (OMV) 5 milligrams (mg) aluminum hydroxide (0.519 mg of Al3+) 125 mg sodium chloride.
Who needs meningococcal B vaccine?
What is meningococcal B?
Meningitis B is one type of meningococcal disease (frequently referred to as meningitis) caused by the bacteria Neisseria meningitidis. Meningitis can attack the brain and spinal cord and cause swelling in those areas as well as a serious infection of the bloodstream, called septicemia.